Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer

W. Brugger, N. Triller, M. Blasinska-Morawiec, S. Curescu, R. Sakalauskas, G. M. Manikhas, J. Mazieres, R. Whittom, C. Ward, K. Mayne, K. Trunzer, F. Cappuzzo
  • Journal of Clinical Oncology, October 2011, American Society of Clinical Oncology (ASCO)
  • DOI: 10.1200/jco.2010.31.8162

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1200/jco.2010.31.8162

The following have contributed to this page: Dr Federico Cappuzzo